5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Highly productive August with pCPA completing 10 negotiations

September 17, 2021
-
Market Access News
-
Posted by MORSE - 5 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): August 2021 Trends and Insights

 

August 2021 Highlights:

  • 8 products completed CADTH review
  • 4 products initiated pCPA negotiations
  • 10 negotiations were completed with an LOI
  • No negotiations were closed without an LOI
  • No files were closed without negotiation

 

Key Take-Aways:

  • The output of the pCPA in August was a high number of completed negotiations and slightly less files initiated for negotiations than usual.
  • Partly due to the high volume of CADTH recommendations finalized in August, pCPA’s under consideration count stands at its highest (35) over this past year. In addition, the number of oncology files under consideration follows the same trend, with a considerable rise and the highest we have seen over the last 12 months, sitting at 16.
  • Four new files initiated negotiations, with 2 of the files being initiated relatively quickly (22, 33 days) while the other two files took 5-6 months to initiate (Entresto which already has a LOI in place and Kesimpta, for MS). The number of active files under negotiation dropped from the annual highs (over 40) seen over the last 2 months, mainly due to the high number of negotiations completed in August. The overall total volume of files under pCPA purview continues to be high with 71 files either under consideration or in active negotiations.
  • The pCPA completed a higher than average number of negotiations in August, including: 3 non-oncology files; 5 oncology files; 2 biosimilar files.
  • There is some consistency being seen for the average time under negotiation which has hovered around the 4-5 month range for the last year. The last 3 months show a trend of more active negotiations compared to previous quarters this year, perhaps signalling increased capacity. As of August 31st, there were 10 files under consideration for greater than 6 months, with two files added to this total in August. In addition, there remain two files under negotiation for greater than 1 year (Darzalex and Botox). Overall, there have been more files adjudicated by the pCPA in August than seen over the past year.

 

Files Under pCPA Consideration*:

CADTH issued 8 new recommendations in August (35 files under pCPA consideration as of Aug. 31st – up from 31 in July).

*Correction: Opdivo & Yervoy (Nivolumab & Ipilimumab in combo) received a final recommendation on July 16, 2021 but were not included in MORSE’s July pCPA update because it wasn’t published on the CADTH website until August.

PRODUCT INDICATION SPONSOR Reimbursement Decision REC’N* DATE

Non-Oncology

Evrysdi (risdiplam) Spinal muscular atrophy Hoffmann-La Roche Limited Conditional Reimbursement 2021-08-05
Jorveza (budesonide) Maintenance of Eosinophilic esophagitis in adults AVIR Pharma Inc. Conditional Reimbursement 2021-08-05
Rinvoq (upadacitinib) Psoriatic Arthritis, Adults. AbbVie Corporation Conditional Reimbursement 2021-08-04
Entuzity KwikPen (human insulin) Diabetes mellitus Eli Lilly Canada Inc. Conditional Reimbursement 2021-08-05

Oncology

Vyxeos (Daunorubicin and Cytarabine) Acute myeloid leukemia Jazz Pharmaceuticals Canada Inc. Conditional Reimbursement 2021-08-06
Tecartus (Brexucabtagene Autoleucel) Mantle cell lymphoma Gilead Sciences Canada Inc. Conditional Reimbursement 2021-08-06
Venclexta (Venetoclax, in combo with cytarabine) Acute myeloid leukemia AbbVie Corporation Conditional Reimbursement 2021-08-05
Venclexta (Venetoclax, in combo with azacitidine ) Acute myeloid leukemia AbbVie Corporation Conditional Reimbursement 2021-08-04

*Note: MORSE defines “Rec’n date” as the time of‘final recommendation issued to sponsor and drug plans’, and the ‘Time to Initiate’ as the time between ‘final recommendation issued to sponsor and drug plans’ and ‘pCPA Engagement Letter Issued’.
 

 

Signals Decoded:

 

Partly due to the high volume of CADTH recommendations finalized in August, pCPA’s under consideration count stands at its highest (35) over this past year.  In addition, the number of oncology files under consideration follows the same trend, with a considerable rise and the highest we have seen over the last 12 months, sitting at 16.

 

Negotiation Initiation:

The pCPA initiated 4 new negotiations in August bringing the number of active negotiations to 36 (as of August 31st), down from 42 in July.

PRODUCT INDICATION SPONSOR INITIATE DATE TTI*

Non Oncology

Kesimpta (ofatumumab) Multiple Sclerosis, relapsing Novartis Pharma Canada Inc. 2021-08-27 183
Entresto (Sacubitril/valsartan) Heart failure, NYHA Class II or III Novartis Pharmaceuticals Canada Inc. 2021-08-20 149
Evrysdi (risdiplam)*** Spinal muscular atrophy Hoffmann-La Roche Limited 2021-08-27 22

Oncology

Keytruda (pembrolizumab)** Colorectal cancer Merck Canada Inc. 2021-08-11 33

*Time to Initiation (TTI) – Time between ‘final recommendation issued to sponsor and drug plans’ and ‘pCPA Engagement Letter Issued’
**initiated and completed pCPA negotiation on the same day
***received CADTH rec’ and initiated pCPA negotiation in the same month

 

 

Signals Decoded:
 
Four new files initiated negotiations, with 2 of the files being initiated relatively quickly (22, 33 days) while the other two files took 5-6 months to initiate (Entresto which already has a LOI in place and Kesimpta, for MS).
 
The 2 files initiated quickly were:

  • Keytruda (for colorectal cancer) which opened and closed on the same day, the same as occurred with their last indication in head and neck squamous cell carcinoma in Feb 2021; and
  • Evrysdi, the third therapy for treatment of SMA, which will join Zolgensma which is currently under active negotiation as well.

The number of active files under negotiation dropped from the annual highs (over 40) seen over the last 2 months, mainly due to the high number of negotiations completed in August. The overall total volume of files under pCPA purview continues to be high with 71 files either under consideration or in active negotiations.

 

Completed Negotiations:

The pCPA completed 10 negotiations with a Letter of Intent (LOI) in August 2021, up from 3 in July.

PRODUCT INDICATION Sponsor Status LOI DATE TTN*

Non-Oncology

Beovu (brolucizumab) Macular degeneration, age-related Novartis Pharma Canada Inc. Completed 2021-08-31 126
Entyvio SC (Vedolizumab) Crohn’s Disease Takeda Canada Inc. Completed 2021-08-13 120
Entyvio  SC (Vedolizumab) Ulcerative Colitis Takeda Canada Inc. Completed 2021-08-13 298

Oncology

Cabometyx (Cabozantinib) Hepatocellular Carcinoma Ipsen Biopharmaceuticals Completed 2021-08-24 273
Zejula (niraparib) Ovarian Cancer GlaxoSmithKline Inc. Completed 2021-08-11 271
Zejula (niraparib) First Line Ovarian Cancer GlaxoSmithKline Inc. Completed 2021-08-11 71
Erleada (Apalutamide) Metastatic Castration-Sensitive Prostate Cancer Janssen Inc. Completed 2021-08-17 312
Keytruda (pembrolizumab) Colorectal cancer Merck Canada Inc. Completed 2021-08-11 0

Biosimilar

Bambevi (bevacizumab) Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) – Glioblastoma Apotex Inc. Completed 2021-08-18 68
Trurapi (insulin aspart) Diabetes Mellitus, Type 1 & 2 Sanofi-Aventis Completed 2021-08-16 111

* TTN = Time to Negotiate in calendar days
 

Closed Negotiations:

The pCPA did not close any negotiations without an LOI in August 2021.
 

Not Negotiated:

The pCPA did not decline any negotiations in August 2021.

 

Signals Decoded:
 
The pCPA completed a higher than average number of negotiations in August, including:

  • 3 non-oncology files (2 negotiations for Entyvio SC with differing CDEC recommendation dates concluding at the same time, and a new entrant Beovu in wet AMD);
  • 5 oncology files (Cabometyx which may have been the impetus for a recent CADTH provisional algorithm in HCC, 2 negotiations for Zejula in ovarian cancer with differing pERC recommendation dates concluding at the same time, Erleada for castration-sensitive prostate cancer which joins Xtandi for this indication which completed pCPA in July, and Keytruda for colorectal cancer)
  • 2 biosimilar files (the first insulin aspart biosimilar and the 4th bevacizumab biosimilar completed).

 

 

 

 

Signals Decoded:
 
There is some consistency being seen for the average time under negotiation which has hovered around the 4-5 month range for the last year.
 
The last 3 months show a trend of more active negotiations compared to previous quarters this year, perhaps signalling increased capacity.
 
As of August 31st, there were 10 files under consideration for greater than 6 months, with two files added to this total in August. In addition, there remain two files under negotiation for greater than 1 year (Darzalex and Botox).

 
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
Another productive month for pCPA negotiations and initiations
NEXT POST →
MORSE Strengthens Public Payer Expertise

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Highly productive August with pCPA completing 10 negotiations